Julia de Ternay
Overview
Explore the profile of Julia de Ternay including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
31
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chapron S, Bonazzi G, Di Lodovico L, de Ternay J, Landmann C, Nourredine M, et al.
J Psychopharmacol
. 2025 Feb;
:2698811241308613.
PMID: 39891564
Background: In the context of the need to increase treatment options for substance use disorders, recent research has evaluated the therapeutic potential of psychedelics. However, there is an incomplete understanding...
2.
Lespine L, Francois D, Haesebaert J, Delile J, Savy M, Tubiana-Rey B, et al.
Front Public Health
. 2024 Dec;
12:1466739.
PMID: 39687727
Background: Dry January is a one-month alcohol abstinence challenge for the general population running since 2013 in the United Kingdom, and 2020 in France. Dry January has gained increasing popularity...
3.
de Ternay J, Nohales L, Fort E, Pelloux S, Coste C, Leblanc P, et al.
Eur Addict Res
. 2024 Dec;
1-12.
PMID: 39631377
Introduction: Substance misuse significantly impairs psychosocial functioning and correlates with many environmental factors, including working conditions. We investigated the influence of working conditions and other determinants on the risk of...
4.
de Ternay J, Meley C, Guerin P, Meige S, Grelaud N, Rolland B, et al.
Int J Drug Policy
. 2024 Nov;
135():104660.
PMID: 39580993
Background: Pregabalin is a drug approved for neuropathic pain, epilepsy and general anxiety disorder. However, pregabalin is also an increasing cause of diversion and misuse, and, for this reason, the...
5.
Nohales L, Fort E, Pelloux S, Coste C, Leblanc P, de Ternay J, et al.
Front Psychol
. 2024 May;
15:1347513.
PMID: 38770261
Introduction: The mental health of residents is a growing significant concern, particularly with respect to hospital and university training conditions. Our goal was to assess the professional, academic, and psychological...
6.
Touali R, Chappuy M, de Ternay J, Berger-Vergiat A, Haesebaert J, Tazarourte K, et al.
J Addict Dis
. 2023 Dec;
42(4):491-499.
PMID: 38048209
Background: Cannabis use frequently starts during adolescence and young adulthood and can induce psychosocial and health consequences. Young people constitute hard-to-reach populations. Emergency departments could constitute a key care setting...
7.
Chappuy M, Lack P, David B, Penavayre G, Thabourey D, Landulpho M, et al.
Harm Reduct J
. 2023 Oct;
20(1):149.
PMID: 37845698
Background: Drug consumption rooms (DCRs) have been developed in cities with open drug scenes, with the aim to reduce drug-related harm. In Lyon, France's second-largest city, there is no distinct...
8.
de Ternay J, Larrieu A, Sauvestre L, Montegue S, Guenin M, Icard C, et al.
Nutrients
. 2022 Dec;
14(23).
PMID: 36500988
Improving physical activity (PA) in patients with alcohol use disorder (AUD) has recently emerged as an important component of the global treatment strategy to improve drinking outcomes and quality of...
9.
de Ternay J, Leblanc P, Michel P, Benyamina A, Naassila M, Rolland B
Harm Reduct J
. 2022 Mar;
19(1):24.
PMID: 35246148
Over the last decade, one-month alcohol abstinence campaigns (OMACs) have been implemented within the general population in an increasing number of countries. We identified the published studies reporting data on...
10.
Nourredine M, Jurek L, Angerville B, Longuet Y, de Ternay J, Derveaux A, et al.
CNS Drugs
. 2021 Feb;
35(2):177-213.
PMID: 33591567
Background And Objective: Topiramate has been approved by the US Food and Drug Administration for the treatment of epilepsy since the 1990s, and it has also been used off-label in...